These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36789652)

  • 21. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
    Tang Z; Yang Y; Zhang Q; Liang T
    Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression levels and significance of nuclear factor-κB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma.
    Zhou Q; Gong Y; Huang F; Lin Q; Zeng B; Li Z; Chen R
    Dig Surg; 2013; 30(4-6):309-16. PubMed ID: 24008372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
    Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
    J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane RRM2-positive cells represent a malignant population with cancer stem cell features in intrahepatic cholangiocarcinoma.
    Zhao Y; Xue S; Wei D; Zhang J; Zhang N; Mao L; Liu N; Zhao L; Yan J; Wang Y; Cai X; Zhu S; Roessler S; Ji J
    J Exp Clin Cancer Res; 2024 Sep; 43(1):255. PubMed ID: 39243109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways.
    Prakobwong S; Gupta SC; Kim JH; Sung B; Pinlaor P; Hiraku Y; Wongkham S; Sripa B; Pinlaor S; Aggarwal BB
    Carcinogenesis; 2011 Sep; 32(9):1372-80. PubMed ID: 21325634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma.
    Xiong F; Wang D; Xiong W; Wang X; Huang WH; Wu GH; Liu WZ; Wang Q; Chen JS; Kuai YY; Wang B; Chen YJ
    J Exp Clin Cancer Res; 2024 May; 43(1):152. PubMed ID: 38812060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K
    J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.
    Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S
    Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo evidence for GDP-fucose transport in the absence of transporter SLC35C1 and putative transporter SLC35C2.
    Lu L; Varshney S; Yuan Y; Wei HX; Tanwar A; Sundaram S; Nauman M; Haltiwanger RS; Stanley P
    J Biol Chem; 2023 Dec; 299(12):105406. PubMed ID: 38270391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression.
    Mancarella S; Serino G; Coletta S; Armentano R; Dituri F; Ardito F; Ruzzenente A; Fabregat I; Giannelli G
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
    Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
    Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6-alkynyl fucose is a bioorthogonal analog for O-fucosylation of epidermal growth factor-like repeats and thrombospondin type-1 repeats by protein O-fucosyltransferases 1 and 2.
    Al-Shareffi E; Chaubard JL; Leonhard-Melief C; Wang SK; Wong CH; Haltiwanger RS
    Glycobiology; 2013 Feb; 23(2):188-98. PubMed ID: 23045360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling.
    Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H
    Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge.
    Carotti S; Zingariello M; Francesconi M; D'Andrea L; Latasa MU; Colyn L; Fernandez-Barrena MG; Flammia RS; Falchi M; Righi D; Pedini G; Pantano F; Bagni C; Perrone G; Rana RA; Avila MA; Morini S; Zalfa F
    Oncogene; 2021 Jun; 40(23):4033-4049. PubMed ID: 34017076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in the SLC35C1 gene, contributing to significant differences in fucosylation patterns, may underlie the diverse phenotypic manifestations observed in leukocyte adhesion deficiency type II patients.
    Skurska E; Szulc B; Kreczko K; Olczak M
    Int J Biochem Cell Biol; 2024 Aug; 173():106602. PubMed ID: 38843991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression.
    Vitali E; Franceschini B; Milana F; Soldani C; Polidoro MA; Carriero R; Kunderfranco P; Trivellin G; Costa G; Milardi G; Di Tommaso L; Torzilli G; Lleo A; Lania AG; Donadon M
    Liver Int; 2024 Feb; 44(2):518-531. PubMed ID: 38010911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity.
    Tomooka F; Kaji K; Nishimura N; Kubo T; Iwai S; Shibamoto A; Suzuki J; Kitagawa K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo.
    Wentz SC; Yip-Schneider MT; Gage EA; Saxena R; Badve S; Schmidt CM
    J Surg Res; 2009 Nov; 157(1):e87-95. PubMed ID: 19564027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.